One Molecule, Two Effects

One Molecule, Two Effects describes a new drug concept developed by a research team at Helmholtz Munich for the treatment of obesity and type 2 diabetes. The approach centers on a hybrid molecule that leverages the GLP-1/GIP signaling pathway as a means to deliver an additional metabolic modulator directly into target cells. This innovation aims to address the challenge of enhancing incretin-based therapies without increasing system-wide side effects often associated with metabolic drugs.

The hybrid molecule is constructed by chemically linking an established incretin active component to lanifibranor, a pan-PPAR agonist. The incretin segment binds to GLP-1 or GIP receptors on cell surfaces, facilitating the uptake of the molecule into the cell. Once inside, the lanifibranor component interacts with PPARs—cellular switches that regulate genes involved in fat and sugar metabolism. This design allows for the additional metabolic effects to be concentrated in cells expressing GLP-1R or GIPR, rather than being distributed throughout the body. As a result, the second component can be used at significantly lower doses, reducing the risk of side effects.

In laboratory experiments with mice suffering from diet-induced obesity, the hybrid molecule led to reduced food intake, greater weight loss, and improved blood glucose levels compared to reference treatments. The study also observed signs of improved insulin action, such as better glucose uptake into tissues and reduced glucose release from the liver. Side effects, particularly gastrointestinal ones, were found to be comparable to existing incretin therapies, and no indications of fluid retention or anemia were reported in the parameters examined. Additional data suggested potentially favorable effects on heart and liver health.

This research is currently at the preclinical stage, with results demonstrated in animal models. The study highlights the need for further development and optimization before clinical application in humans can be considered, given differences in receptor biology between species. The work is led by Prof. Timo D. Müller at Helmholtz Munich, in collaboration with the Ludwig Maximilian University of Munich and the German Center for Diabetes Research.